These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 1997632

  • 1. Chemotactic activity and receptor binding of neutrophil attractant/activation protein-1 (NAP-1) and structurally related host defense cytokines: interaction of NAP-2 with the NAP-1 receptor.
    Leonard EJ, Yoshimura T, Rot A, Noer K, Walz A, Baggiolini M, Walz DA, Goetzl EJ, Castor CW.
    J Leukoc Biol; 1991 Mar; 49(3):258-65. PubMed ID: 1997632
    [Abstract] [Full Text] [Related]

  • 2. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils.
    Walz A, Dewald B, von Tscharner V, Baggiolini M.
    J Exp Med; 1989 Nov 01; 170(5):1745-50. PubMed ID: 2681518
    [Abstract] [Full Text] [Related]

  • 3. Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2.
    Härter L, Petersen F, Flad HD, Brandt E.
    J Immunol; 1994 Dec 15; 153(12):5698-708. PubMed ID: 7989767
    [Abstract] [Full Text] [Related]

  • 4. Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G.
    Schiemann F, Grimm TA, Hoch J, Gross R, Lindner B, Petersen F, Bulfone-Paus S, Brandt E.
    Blood; 2006 Mar 15; 107(6):2234-42. PubMed ID: 16317101
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Structure and bioactivity of recombinant human CTAP-III and NAP-2.
    Proudfoot AE, Peitsch MC, Power CA, Allet B, Mermod JJ, Bacon K, Wells TN.
    J Protein Chem; 1997 Jan 15; 16(1):37-49. PubMed ID: 9055206
    [Abstract] [Full Text] [Related]

  • 7. Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III.
    Brandt E, Van Damme J, Flad HD.
    Cytokine; 1991 Jul 15; 3(4):311-21. PubMed ID: 1873479
    [Abstract] [Full Text] [Related]

  • 8. Regulation of glucose transporters by connective tissue activating peptide-III isoforms.
    Tai PK, Liao JF, Hossler PA, Castor CW, Carter-Su C.
    J Biol Chem; 1992 Sep 25; 267(27):19579-86. PubMed ID: 1527075
    [Abstract] [Full Text] [Related]

  • 9. Structural requirements of platelet chemokines for neutrophil activation.
    Yan Z, Zhang J, Holt JC, Stewart GJ, Niewiarowski S, Poncz M.
    Blood; 1994 Oct 01; 84(7):2329-39. PubMed ID: 7919350
    [Abstract] [Full Text] [Related]

  • 10. Leukocyte specificity and binding of human neutrophil attractant/activation protein-1.
    Leonard EJ, Skeel A, Yoshimura T, Noer K, Kutvirt S, Van Epps D.
    J Immunol; 1990 Feb 15; 144(4):1323-30. PubMed ID: 2406341
    [Abstract] [Full Text] [Related]

  • 11. Novel C-terminally truncated isoforms of the CXC chemokine beta-thromboglobulin and their impact on neutrophil functions.
    Ehlert JE, Gerdes J, Flad HD, Brandt E.
    J Immunol; 1998 Nov 01; 161(9):4975-82. PubMed ID: 9794434
    [Abstract] [Full Text] [Related]

  • 12. The amino-terminal residues in the crystal structure of connective tissue activating peptide-III (des10) block the ELR chemotactic sequence.
    Malkowski MG, Lazar JB, Johnson PH, Edwards BF.
    J Mol Biol; 1997 Feb 21; 266(2):367-80. PubMed ID: 9047370
    [Abstract] [Full Text] [Related]

  • 13. Human neutrophil Fc gamma RIIIB and formyl peptide receptors are functionally linked during formyl-methionyl-leucyl-phenylalanine-induced chemotaxis.
    Kew RR, Grimaldi CM, Furie MB, Fleit HB.
    J Immunol; 1992 Aug 01; 149(3):989-97. PubMed ID: 1321856
    [Abstract] [Full Text] [Related]

  • 14. High- and low-affinity binding of GRO alpha and neutrophil-activating peptide 2 to interleukin 8 receptors on human neutrophils.
    Schumacher C, Clark-Lewis I, Baggiolini M, Moser B.
    Proc Natl Acad Sci U S A; 1992 Nov 01; 89(21):10542-6. PubMed ID: 1438244
    [Abstract] [Full Text] [Related]

  • 15. Relationship between neutrophil-binding affinity and suitability for infection imaging: comparison of (99m)Tc-labeled NAP-2 (CXCL-7) and 3 C-terminally truncated isoforms.
    Rennen HJ, Frielink C, Brandt E, Zaat SA, Boerman OC, Oyen WJ, Corstens FH.
    J Nucl Med; 2004 Jul 01; 45(7):1217-23. PubMed ID: 15235069
    [Abstract] [Full Text] [Related]

  • 16. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein.
    Ehlert JE, Ludwig A, Grimm TA, Lindner B, Flad HD, Brandt E.
    Blood; 2000 Nov 01; 96(9):2965-72. PubMed ID: 11049972
    [Abstract] [Full Text] [Related]

  • 17. Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration.
    Schenk BI, Petersen F, Flad HD, Brandt E.
    J Immunol; 2002 Sep 01; 169(5):2602-10. PubMed ID: 12193731
    [Abstract] [Full Text] [Related]

  • 18. Neutrophil-endothelial cell interactions. Modulation of neutrophil adhesiveness induced by complement fragments C5a and C5a des arg and formyl-methionyl-leucyl-phenylalanine in vitro.
    Tonnesen MG, Smedly LA, Henson PM.
    J Clin Invest; 1984 Nov 01; 74(5):1581-92. PubMed ID: 6501563
    [Abstract] [Full Text] [Related]

  • 19. Formation of neutrophil-activating peptide 2 from platelet-derived connective-tissue-activating peptide III by different tissue proteinases.
    Car BD, Baggiolini M, Walz A.
    Biochem J; 1991 May 01; 275 ( Pt 3)(Pt 3):581-4. PubMed ID: 2039437
    [Abstract] [Full Text] [Related]

  • 20. The unique property of the CC chemokine regakine-1 to synergize with other plasma-derived inflammatory mediators in neutrophil chemotaxis does not reside in its NH2-terminal structure.
    Gouwy M, Struyf S, Mahieu F, Put W, Proost P, Van Damme J.
    Mol Pharmacol; 2002 Jul 01; 62(1):173-80. PubMed ID: 12065768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.